Clinical Trials Browser

Not yet recruiting × OTHER × Stem Cell Transplantation × Clear all

NCT07349771 2026-04-16

Axatilimab Plus Standard of Care Therapy for the Prevention of Graft Versus Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Cancer, ABRAXAS Trial

Phase 2 Not yet recruiting

Hematopoietic and Lymphatic System Neoplasm

NCT04579523 2026-03-13

²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma

Phase 1 Not yet recruiting

Multiple Myeloma

NCT07365306 2026-01-26

Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Phase 2 Not yet recruiting

Lymphoma, Large B-Cell, Diffuse

NCT07358195 2026-01-22

Addition of Venetoclax to Combined Hematopoietic Stem Cell and Kidney Transplantation

Phase EARLY_PHASE1 Not yet recruiting

Other hematologic neoplasm

Hematologic Neoplasms, Renal Insufficiency, Chronic

NCT06996119 2025-05-30

Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant

Phase 1 Not yet recruiting

MyeloidOther hematologic neoplasm

Graft vs Host Disease, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute